SCHEMBL4464443

SCHEMBL4464443

CC(=O)Nc1ccc(SC2=NNC(=O)C2=C2C=Cc3ccccc3N2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
PTPN1 P18031 1/20 0.40
CDC25A P30304 1/20 0.40
CDC25B P30305 1/20 0.40
PTGS2 P35354 1/20 0.37
MAOA P21397 1/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
SCN2A Q99250 1/20 0.34
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
MAPT P10636 3/20 0.34
GAA P10253 3/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
AURKA O14965 3/20 0.34
SRC P12931 2/20 0.34
GSK3B P49841 2/20 0.34
POLB P06746 2/20 0.34
HSD17B10 Q99714 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464440 1.00 SMN1; SMN2 (0.41) SMN1; SMN2PTPN1CDC25ACDC25BPTGS2
SCHEMBL5999321 0.88 PKM (0.34) SMN1; SMN2PTPN1CDC25ACDC25BKMT2A
SCHEMBL4462771 0.88 PKM (0.34) SMN1; SMN2PTPN1CDC25ACDC25BKMT2A
SCHEMBL4470643 0.82 MAPT (0.42) SMN1; SMN2MAOASCN2AKMT2AMEN1
SCHEMBL4470653 0.82 MAPT (0.42) SMN1; SMN2MAOASCN2AKMT2AMEN1
SCHEMBL4461277 0.81 GAA (0.36) MAPTGAACYP3A4
SCHEMBL4461273 0.81 GAA (0.36) MAPTGAACYP3A4
SCHEMBL4460455 0.79 SMN1; SMN2 (0.41) SMN1; SMN2PTPN1MAOAKMT2AMEN1
SCHEMBL4460453 0.79 SMN1; SMN2 (0.41) SMN1; SMN2PTPN1MAOAKMT2AMEN1
SCHEMBL4462876 0.79 MAPT (0.38) SMN1; SMN2MAOAKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 US claimed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 EP claimed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 WO claimed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 US claimed
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 US disclosed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 EP disclosed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 WO disclosed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060041137-A1 Kinase inhibitors MAP3K19, MAP3K20, MAP3K1 SMN1; SMN2 4388/4885PTPN1 647/4885CDC25A 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.